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Consider a drug which millions of
people have used during the past five
millennia, but which has never killed
anyone. A drug which has been
claimed to be effective against a
variety of disorders including the
spasms of people with multiple
sclerosis and the weight loss of AIDS
and chemotherapy patients. A drug
which is cheap and easy to
administer and although taken for
pleasure by many people, is
considered by many to be less
addictive than alcohol, tobacco, or
chocolate. And a drug which, by the
way, is made from the same
immensely useful plant as the paper
on which both the Gutenberg bible
and the American declaration of
independence were printed. 
The drug still exists, but
possession of small quantities of it
can land you in jail in most countries.
After a period of widespread use and
praise in the 19th century (yes,
Queen Victoria used it, too),
prohibition struck hard, and modern
medical research into its potential
uses has been massively hindered by
political obstruction backed by little
scientific evidence. The drug in
question is produced from the dried
leaves of the hemp Cannabis sativa,
and it is known — whisper it — as
cannabis or marijuana. 
After many years of public
debate, and 25 years after the Dutch
government made possession of
small quantities legal, the British
government has now announced it
will downgrade cannabis from a Class
B to a Class C drug, but it stresses
that this move is conditional on the
approval of the Advisory Council on
the Misuse of Drugs, which was
asked for views on this question
within three months. If approved, the
move would imply that cannabis
would be set further apart from the
“hard” Class A drugs (including
heroin, cocaine, ecstasy and LSD),
and be grouped together with
substances like anabolic steroids.
This reclassification would
effectively remove police powers to
arrest people for possession of the
drug, although dealers can still be
prosecuted. 
Modern medical research into its
potential uses has been
massively hindered
This move follows rethinking in
several countries about cannabis,
particularly concerning potential
medical use. Canada was the first
country to legalize trials on the
medical use of cannabis and others
are likely to follow this path.
Apart from freeing police from
the unpleasant task of jailing people
for a crime that doesn’t produce any
victims, it is also hoped that this
move will finally allow researchers
to take a fresh and thorough look at
the benefits that the cannabis plant
and its many ingredients have to
offer. Those known so far come with
a variable degree of scientific
backing. The German ministry of
health and national chamber of
physicians — both slightly less hung-
up than the British and American
governments, but still rigorously
against legalization of recreational
pot smoking — have ranked the
reported effects in decreasing order
of credibility as follows:
1. Well-established effects:
against nausea, anorexia, and weight
loss.
2. Relatively well established
effects: against spasms, chronic pain,
motion disorders, asthma, glaucoma
(a common cause of blindness).
3. Less well documented:
allergies, itches, infections, epilepsy,
depression, and other psychic
disorders.
4. In need of fundamental
research: autoimmune diseases,
cancer, protective neuronal effects,
fever and abnormal blood pressure. 
At least for the first two groups of
disorders, experts generally agree
that either cannabis or some of its
active substances should be made
available in some form or shape. But
exactly in which form or shape, that
is the question which leads to the
next hang-up. Because in its most
widely used form, the crude
marijuana that people smoke,
cannabis is a ‘dirty drug’ in that it
floods the user with hundreds of
different compounds often in poorly
reproducible quantities, which makes
it difficult if not impossible to design
normal clinical trials.
Many doctors would prefer to
have a purer product with only one or
a few of the active ingredients, and in
a more conventional form of uptake.
(Somehow, the words ‘smoke this
three times a day’ are incredibly
difficult for a doctor to speak!) So far,
the main cannabinoid,
tetrahydrocannabinol (THC or
dronabinol) is registered as an anti-
emetic (i.e. against nausea) in the
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USA, while a synthetic derivative,
nabilone, is available in the UK, but
only for the use in hospitals, and only
against chemotherapy-induced
nausea which is found resistant to
other drugs. 
Neither of the two cannabinoids
is very popular or widely used as a
drug. Many patients who have tried
both the dirty and the clean products
claim that the natural mixture works
best for them. Many have also cited
as an advantage the fact that smoking
a joint allows you to fine-tune the
dose as it is taking effect, while
swallowing a pill does not give you
this level of control. The only major
problem which patients who use
cannabis for medical reasons report is
a legal one: in order to get a
reproducible quality and dosage, they
need to either buy large quantities or
grow their own. Both strategies, of
course, are more likely to get them
locked up than the medically less
advisable way of buying small
quantities at a time. 
Novel ways of administering the
drug may help to reconcile the
wishes of doctors and patients. One
promising avenue is a solution of
cannabis ingredients developed by
the group of Roger Pertwee at the
University of Aberdeen, that would
be suitable to be administered as a
spray. 
The British government has
backed a major trial of cannabis to
see if there is a scientific basis for its
use as a medicine. One component,
involved 23 patients suffering from
multiple sclerosis and arthritis, who
were recruited onto an initial trial
and given daily doses of cannabis as a
spray under the tongue. Researchers
found that up to 80 per cent of the
patients were getting good-quality
improvements from the use of the
cannabis spray. With some promising
results a larger trial is now under way
using cannabis grown specially at a
secret location in southern England.
Clearly, more research is needed into
scientifically sound and reproducible
ways of making the most of the
natural products that hemp has to
offer. The British public has
approved in overwhelmingly positive
opinion polls, the fact that AIDS,
cancer or MS patients will no longer
be put in jail for trying to alleviate
their suffering by smoking cannabis. 
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Leaves of contention: Cannabis plants
shown here growing illegally but attitudes in
many countries are now shifting towards
proper appraisal of the many potential uses
that come from historical and anecdotal
sources and changes in the criminal status of
possesing the drug.
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